A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-28
DOI
10.1007/s10637-020-01058-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
- (2018) Robert H. Andtbacka et al. CANCER RESEARCH
- Abstract 4155: Regulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist
- (2016) David J. Panka et al. CANCER RESEARCH
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemokine signaling in development and disease
- (2014) J. Wang et al. DEVELOPMENT
- CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
- (2014) Margaret Gil et al. JOURNAL OF IMMUNOLOGY
- KRAS and Cancer Stem Cells in APC-Mutant Colorectal Cancer
- (2014) E. R. Fearon et al. JNCI-Journal of the National Cancer Institute
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
- (2013) D Bedognetti et al. BRITISH JOURNAL OF CANCER
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer
- (2011) E. Righi et al. CANCER RESEARCH
- PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
- (2011) N. Obermajer et al. CANCER RESEARCH
- Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary
- (2011) Ryuichiro Sekiya et al. HUMAN PATHOLOGY
- Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
- (2011) R Parameswaran et al. LEUKEMIA
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice
- (2010) Mitomu Kioi et al. JOURNAL OF CLINICAL INVESTIGATION
- High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
- (2009) R Maréchal et al. BRITISH JOURNAL OF CANCER
- Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1
- (2009) Graeme Moyle et al. CLINICAL INFECTIOUS DISEASES
- Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers
- (2008) Y. J. Cao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers
- (2008) Myaing M Nyunt et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Preferential Expression of Chemokine Receptor CXCR4 by Highly Malignant Human Gliomas and Its Association with Poor Patient Survival
- (2008) Moneeb Ehtesham et al. NEUROSURGERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started